Bocidelpar + Placebo
Phase 2Terminated 2 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Mitochondrial Myopathy
Conditions
Primary Mitochondrial Myopathy
Trial Timeline
May 24, 2021 → May 8, 2024
NCT ID
NCT04641962About Bocidelpar + Placebo
Bocidelpar + Placebo is a phase 2 stage product being developed by Astellas Pharma for Primary Mitochondrial Myopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04641962. Target conditions include Primary Mitochondrial Myopathy.
What happened to similar drugs?
20 of 20 similar drugs in Primary Mitochondrial Myopathy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04855201 | Phase 1 | Terminated |
| NCT04641962 | Phase 2 | Terminated |
| NCT04184882 | Phase 1 | Terminated |
Competing Products
20 competing products in Primary Mitochondrial Myopathy